Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2013-01-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
terlipressin
Terlipressin
continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
norepinephrine
Norepinephrine
continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Terlipressin
continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
Norepinephrine
continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregancy or breast-feeding;
* malignancy or other irreversible disease or condition for which has a poor prognosis;
* acute coronary syndrome;
* chronic heart failure(NYHA III or IV)/cardiogenic shock;
* acute mesenteric ischemia;
* greater than 48 hours had elapsed since the patient met entry criteria;
* estimation of incomplite treament due to financial problem;
* use of terlipressin for blood pressure support before entry;
* Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;
* registration of other clinical trial which will affect the outcome of the current study
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Province, Department of Science and Technology
OTHER_GOV
Second Affiliated Hospital, Sun Yat-Sen University
OTHER
Sixth Affiliated Hospital, Sun Yat-sen University
OTHER
Chinese PLA General Hospital
OTHER
Beijing 302 Hospital
OTHER
Shanghai Changzheng Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Xiangya Hospital of Central South University
OTHER
Anhui Provincial Hospital
OTHER_GOV
The First Affiliated Hospital of Bengbu Medical University
OTHER
Guangxi Medical University
OTHER
Jinling Hospital, China
OTHER
West China Hospital
OTHER
Hainan People's Hospital
OTHER
Xi'an Jiaotong University
OTHER
China Medical University, China
OTHER
First People's Hospital of Foshan
OTHER
ZhuHai Hospital
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guan XiangDong
director of surgical intensive care unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guan XiangDong, doctor
Role: STUDY_CHAIR
first affiliated hospital SunYetSen university
liu ZiMeng, M.D
Role: STUDY_DIRECTOR
first affiliated hospital ,SunYetSen university
Si Xiang, M.D.
Role: PRINCIPAL_INVESTIGATOR
first affiliated hospital ,SunYetSen university
Chen Juan, M.D.
Role: PRINCIPAL_INVESTIGATOR
first affiliated hospital ,SunYetSen university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Surgical intensive care unit, 1st affiliated hospital of Sun Yat-sen university
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Guan Xiangdong, M.D.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Liu ZM, Chen J, Kou Q, Lin Q, Huang X, Tang Z, Kang Y, Li K, Zhou L, Song Q, Sun T, Zhao L, Wang X, He X, Wang C, Wu B, Lin J, Yuan S, Gu Q, Qian K, Shi X, Feng Y, Lin A, He X; Study Group of investigators; Guan XD. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med. 2018 Nov;44(11):1816-1825. doi: 10.1007/s00134-018-5267-9. Epub 2018 Jul 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012A080204018;2007015
Identifier Type: -
Identifier Source: org_study_id